<DOC>
	<DOCNO>NCT00634907</DOCNO>
	<brief_summary>Several human gene affect medication metabolize body . It believe knowledge variation gene help health care provider well manage anticoagulation medicine call warfarin ( Coumadin® ) result decrease patient problem bleed development blood clot . This study design evaluate genetic test improve warfarin initiation well usual care .</brief_summary>
	<brief_title>Prospective Genotyping For Total Hip Knee Replacement Patients Receiving Warfarin ( Coumadin )</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Participants otherwise healthy adult ( ≥ 18 year age ) planning total hip knee replacement revision surgery University Utah Hospital , schedule preoperative office visit University Utah Orthopaedic Center . Blood transfusion previous two week Participant already take warfarin Preoperative INR &gt; 4.0 Preoperative bilirubin &gt; 2.4 mg/dL Current active cancer diagnosis ongoing treatment Concomitant medication know exert major interaction warfarin septra , metronidazole , tramadol , amiodarone , ciprofloxacin , cimetidine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Genotyping</keyword>
	<keyword>Warfarin dosing</keyword>
	<keyword>arthroplasty</keyword>
</DOC>